The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.
© Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.Study finds long-acting shot helps women avoid HIV infection
By MARILYNN MARCHIONE NEW YORK©2024 GPlusMedia Inc.
2 Comments
Login to comment
Jonathan Prin
Cost of a shot compare to pills ?
And it is not a scientific study. It is a practical study only.
If it just limit spreading over time, it is just leaving more time to live but not avoid catching it in the long term...
virusrex
That makes no sense, methods is what make a study scientific or not, a practical application is irrelevant for this, the trial is HPTN 084, a "phase 3 double blind safety and efficacy study of long-acting injectable Cabotegravir compared to daily roal TDF/FTC for pre-exposure prophylaxis in HIV-uninfected women."
This would mean is a scientific study no matter how you want to define it.
And no, what is spreading over time is the dosing, the effect is the same, preventing infection. The inyectable version is not yet priced but the Truvada pills are about $2,000 a month, so it is quite easy to make it cost effective, especially taking in account adherence to the method which is a problem for all daily oral formulations. It is also easier to include in medical insurance plans because it can be controlled more closely and is less susceptible to be abused.